IMDX

6.45

5.91% 0.36

Handel nachbörslich: 6.44 -0.010 -0.16%

Insight Molecular Diagnostics Inc (IMDX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$6.09

Offen:

$6.16

24-Stunden-Volumen:

268.76K

Relative Volume:

0.83

Marktkapitalisierung:

$208.59M

Einnahmen:

$4.06M

Nettoeinkommen (Verlust:

$-50.22M

KGV:

-3.9852

EPS:

-1.6185

Netto-Cashflow:

$-25.37M

1W Leistung:

+16.01%

1M Leistung:

+71.54%

6M Leistung:

+6.79%

1J Leistung:

+0.00%

1-Tages-Spanne:

$6.05

$6.71

1-Wochen-Bereich:

$5.43

$6.71

52-Wochen-Spanne:

$2.33

$8.51

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Firmenname

Insight Molecular Diagnostics Inc

Sektor

Healthcare (1113)

Branche

Diagnostics & Research (52)

Telefon

949-409-7600

Adresse

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-05-13

Neueste SEC-Einreichungen

IMDX's Discussions on Twitter

Compare IMDX vs TMO, DHR, IDXX, WAT, A

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IMDX Insight Molecular Diagnostics Inc	6.46	196.65M	4.06M	-50.22M	-25.37M	-1.6185
TMO Thermo Fisher Scientific Inc	448.27	166.59B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	172.86	121.74B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	557.15	44.12B	4.45B	1.10B	1.06B	13.59
WAT Waters Corp	338.72	33.62B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	115.09	32.49B	7.07B	1.29B	993.00M	4.5355

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-28	Eingeleitet	Lake Street	Buy
2022-05-24	Herabstufung	Stephens	Overweight → Equal-Weight
2022-03-14	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2022-01-07	Eingeleitet	Stephens	Overweight
2022-01-06	Fortgesetzt	Piper Sandler	Overweight
2021-03-17	Fortgesetzt	Needham	Buy
2021-01-07	Hochstufung	The Benchmark Company	Speculative Buy → Buy
2020-12-16	Hochstufung	Piper Sandler	Neutral → Overweight
2020-11-30	Eingeleitet	BTIG Research	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2020-07-30	Bestätigt	The Benchmark Company	Speculative Buy
2020-07-01	Herabstufung	Piper Sandler	Overweight → Neutral
2020-06-30	Herabstufung	Chardan Capital Markets	Buy → Neutral
2020-06-02	Eingeleitet	Needham	Buy
2019-02-13	Eingeleitet	Piper Jaffray	Overweight
2019-01-29	Hochstufung	Janney	Neutral → Buy
2018-12-19	Fortgesetzt	Lake Street	Buy

Alle ansehen

Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten

May 20, 2026

Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia

May 20, 2026

Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks

May 20, 2026

May 17, 2026

Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha

May 17, 2026

May 15, 2026

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail

May 15, 2026

How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance

May 15, 2026

BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria

May 15, 2026

BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India

May 15, 2026

Insight Molecular Q1 2026 Earnings Call Transcript - Sahm

May 15, 2026

May 14, 2026

Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 14, 2026